A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24‐month results from FACTS‐International
Identifieur interne : 008900 ( Main/Exploration ); précédent : 008899; suivant : 008901A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24‐month results from FACTS‐International
Auteurs : D. M. Reid [Royaume-Uni] ; D. Hosking [Royaume-Uni] ; D. Kendler [Canada] ; M. L. Brandi [Italie] ; J. D. Wark [Australie] ; J. F. Marques-Neto [Brésil] ; G. Weryha [France] ; N. Verbruggen [États-Unis] ; C. M. Hustad [États-Unis] ; E. M. Mahlis [États-Unis] ; M. E. Melton [États-Unis]Source :
- International Journal of Clinical Practice [ 1368-5031 ] ; 2008-04.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Adulte, Collecte de données, Chiffre d'affaires, Femme, Médecine.
English descriptors
- KwdEn :
- Adult, Alendronate, Alendronate risedronate, Alendronic acid, Antiosteoclastic agent, Antiosteoporotic, Antiresorptive, Antiresorptive agent, Antiresorptive agents, April, Base study, Baseline, Baseline month, Biochemical markers, Blackwell publishing, Bone density, Bone miner, Bone mineral density, Bone resorption, Bone strength, Bone turnover, Bone turnover markers, Clin, Clin endocrinol metab, Clin pract, Cohort, Comparative study, Critical revision, Data collection, Data interpretation, Extension study, Female, Femoral, Femoral neck, Fracture, Fracture intervention trial, Fracture rates, Fracture risk, Fracture risk reductions, Greater increases, International, Journal compilation, Lumbar, Lumbar spine, Marker, Medicine, Merck, Nonvertebral fractures, Osteoporosis, Percent change, Percentage change, Postmenopausal, Postmenopausal osteoporosis, Postmenopausal women, Postmenopause, Pract, Resorption, Result, Risedronate, Risedronate treatment, Risedronic acid, Study medication, Surrogate, Time points, Tolerability, Treatment difference, Treatment differences, Treatment groups, Trochanter, Turnover, Vertebral, Vertebral fracture, Vertebral fractures, Whitehouse, Whitehouse station, Woman, World.
- Teeft :
- Alendronate, Alendronate risedronate, Antiresorptive, Antiresorptive agents, April, Base study, Baseline, Baseline month, Biochemical markers, Blackwell publishing, Bone density, Bone miner, Bone mineral density, Bone resorption, Bone strength, Bone turnover, Bone turnover markers, Clin, Clin endocrinol metab, Clin pract, Cohort, Critical revision, Data collection, Data interpretation, Extension study, Femoral, Femoral neck, Fracture, Fracture intervention trial, Fracture rates, Fracture risk, Fracture risk reductions, Greater increases, Journal compilation, Lumbar, Lumbar spine, Marker, Merck, Nonvertebral fractures, Osteoporosis, Percent change, Percentage change, Postmenopausal, Postmenopausal osteoporosis, Postmenopausal women, Pract, Resorption, Risedronate, Risedronate treatment, Study medication, Surrogate, Time points, Tolerability, Treatment difference, Treatment differences, Treatment groups, Trochanter, Turnover, Vertebral, Vertebral fracture, Vertebral fractures, Whitehouse, Whitehouse station.
Abstract
Objectives: To compare alendronate 70 mg once weekly (OW) with risedronate 35 mg OW with respect to change in bone mineral density (BMD), biochemical markers and upper gastrointestinal (UGI) tolerability over 24 months.
Url:
DOI: 10.1111/j.1742-1241.2008.01704.x
Affiliations:
- Australie, Brésil, Canada, France, Italie, Royaume-Uni, États-Unis
- Grand Est, Lorraine (région), New Jersey, Victoria (État), État de São Paulo
- Melbourne, Nancy, São Paulo
- Université de Melbourne
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000617
- to stream Istex, to step Curation: 000617
- to stream Istex, to step Checkpoint: 001268
- to stream Main, to step Merge: 009162
- to stream PascalFrancis, to step Corpus: 003670
- to stream PascalFrancis, to step Curation: 002976
- to stream PascalFrancis, to step Checkpoint: 003465
- to stream Main, to step Merge: 009879
- to stream Main, to step Curation: 008900
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24‐month results from FACTS‐International</title><author><name sortKey="Reid, D M" sort="Reid, D M" uniqKey="Reid D" first="D. M." last="Reid">D. M. Reid</name></author><author><name sortKey="Hosking, D" sort="Hosking, D" uniqKey="Hosking D" first="D." last="Hosking">D. Hosking</name></author><author><name sortKey="Kendler, D" sort="Kendler, D" uniqKey="Kendler D" first="D." last="Kendler">D. Kendler</name></author><author><name sortKey="Brandi, M L" sort="Brandi, M L" uniqKey="Brandi M" first="M. L." last="Brandi">M. L. Brandi</name></author><author><name sortKey="Wark, J D" sort="Wark, J D" uniqKey="Wark J" first="J. D." last="Wark">J. D. Wark</name></author><author><name sortKey="Marques Eto, J F" sort="Marques Eto, J F" uniqKey="Marques Eto J" first="J. F." last="Marques-Neto">J. F. Marques-Neto</name></author><author><name sortKey="Weryha, G" sort="Weryha, G" uniqKey="Weryha G" first="G." last="Weryha">G. Weryha</name></author><author><name sortKey="Verbruggen, N" sort="Verbruggen, N" uniqKey="Verbruggen N" first="N." last="Verbruggen">N. Verbruggen</name></author><author><name sortKey="Hustad, C M" sort="Hustad, C M" uniqKey="Hustad C" first="C. M." last="Hustad">C. M. Hustad</name></author><author><name sortKey="Mahlis, E M" sort="Mahlis, E M" uniqKey="Mahlis E" first="E. M." last="Mahlis">E. M. Mahlis</name></author><author><name sortKey="Melton, M E" sort="Melton, M E" uniqKey="Melton M" first="M. E." last="Melton">M. E. Melton</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:207451C66668188CD2675BB430BD2EFDB6B6E70C</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1111/j.1742-1241.2008.01704.x</idno><idno type="url">https://api.istex.fr/document/207451C66668188CD2675BB430BD2EFDB6B6E70C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000617</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000617</idno><idno type="wicri:Area/Istex/Curation">000617</idno><idno type="wicri:Area/Istex/Checkpoint">001268</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001268</idno><idno type="wicri:doubleKey">1368-5031:2008:Reid D:a:comparison:of</idno><idno type="wicri:Area/Main/Merge">009162</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:08-0176597</idno><idno type="wicri:Area/PascalFrancis/Corpus">003670</idno><idno type="wicri:Area/PascalFrancis/Curation">002976</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003465</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003465</idno><idno type="wicri:doubleKey">1368-5031:2008:Reid D:a:comparison:of</idno><idno type="wicri:Area/Main/Merge">009879</idno><idno type="wicri:Area/Main/Curation">008900</idno><idno type="wicri:Area/Main/Exploration">008900</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24‐month results from FACTS‐International</title><author><name sortKey="Reid, D M" sort="Reid, D M" uniqKey="Reid D" first="D. M." last="Reid">D. M. Reid</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medicine & Therapeutics, University of Aberdeen, Aberdeen</wicri:regionArea><wicri:noRegion>Aberdeen</wicri:noRegion></affiliation></author><author><name sortKey="Hosking, D" sort="Hosking, D" uniqKey="Hosking D" first="D." last="Hosking">D. Hosking</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Bone and Mineral Metabolism, Nottingham City Hospital, Nottingham</wicri:regionArea><wicri:noRegion>Nottingham</wicri:noRegion></affiliation></author><author><name sortKey="Kendler, D" sort="Kendler, D" uniqKey="Kendler D" first="D." last="Kendler">D. Kendler</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Providence Health Care, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Brandi, M L" sort="Brandi, M L" uniqKey="Brandi M" first="M. L." last="Brandi">M. L. Brandi</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine, University of Florence, Florence</wicri:regionArea><wicri:noRegion>Florence</wicri:noRegion></affiliation></author><author><name sortKey="Wark, J D" sort="Wark, J D" uniqKey="Wark J" first="J. D." last="Wark">J. D. Wark</name><affiliation wicri:level="4"><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medicine and Bone & Mineral Service, University of Melbourne, Royal Melbourne Hospital, Parkville, Vic.</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Marques Eto, J F" sort="Marques Eto, J F" uniqKey="Marques Eto J" first="J. F." last="Marques-Neto">J. F. Marques-Neto</name><affiliation wicri:level="3"><country xml:lang="fr">Brésil</country><wicri:regionArea>Department of Rheumatology, State University (Unicamp), Campinas, São Paulo</wicri:regionArea><placeName><settlement type="city">São Paulo</settlement><region type="state">État de São Paulo</region></placeName></affiliation></author><author><name sortKey="Weryha, G" sort="Weryha, G" uniqKey="Weryha G" first="G." last="Weryha">G. Weryha</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Service d’Endocrinologie, Hôpital de Brabois, Nancy</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Lorraine (région)</region><settlement type="city">Nancy</settlement></placeName></affiliation></author><author><name sortKey="Verbruggen, N" sort="Verbruggen, N" uniqKey="Verbruggen N" first="N." last="Verbruggen">N. Verbruggen</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck & Co., Inc., Whitehouse Station, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Hustad, C M" sort="Hustad, C M" uniqKey="Hustad C" first="C. M." last="Hustad">C. M. Hustad</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck & Co., Inc., Whitehouse Station, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Mahlis, E M" sort="Mahlis, E M" uniqKey="Mahlis E" first="E. M." last="Mahlis">E. M. Mahlis</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck & Co., Inc., Whitehouse Station, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Melton, M E" sort="Melton, M E" uniqKey="Melton M" first="M. E." last="Melton">M. E. Melton</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck & Co., Inc., Whitehouse Station, NJ</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">International Journal of Clinical Practice</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF CLINICAL PRACTICE</title><idno type="ISSN">1368-5031</idno><idno type="eISSN">1742-1241</idno><imprint><biblScope unit="vol">62</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="575">575</biblScope><biblScope unit="page" to="584">584</biblScope><biblScope unit="page-count">10</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2008-04">2008-04</date></imprint><idno type="ISSN">1368-5031</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1368-5031</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Alendronate</term><term>Alendronate risedronate</term><term>Alendronic acid</term><term>Antiosteoclastic agent</term><term>Antiosteoporotic</term><term>Antiresorptive</term><term>Antiresorptive agent</term><term>Antiresorptive agents</term><term>April</term><term>Base study</term><term>Baseline</term><term>Baseline month</term><term>Biochemical markers</term><term>Blackwell publishing</term><term>Bone density</term><term>Bone miner</term><term>Bone mineral density</term><term>Bone resorption</term><term>Bone strength</term><term>Bone turnover</term><term>Bone turnover markers</term><term>Clin</term><term>Clin endocrinol metab</term><term>Clin pract</term><term>Cohort</term><term>Comparative study</term><term>Critical revision</term><term>Data collection</term><term>Data interpretation</term><term>Extension study</term><term>Female</term><term>Femoral</term><term>Femoral neck</term><term>Fracture</term><term>Fracture intervention trial</term><term>Fracture rates</term><term>Fracture risk</term><term>Fracture risk reductions</term><term>Greater increases</term><term>International</term><term>Journal compilation</term><term>Lumbar</term><term>Lumbar spine</term><term>Marker</term><term>Medicine</term><term>Merck</term><term>Nonvertebral fractures</term><term>Osteoporosis</term><term>Percent change</term><term>Percentage change</term><term>Postmenopausal</term><term>Postmenopausal osteoporosis</term><term>Postmenopausal women</term><term>Postmenopause</term><term>Pract</term><term>Resorption</term><term>Result</term><term>Risedronate</term><term>Risedronate treatment</term><term>Risedronic acid</term><term>Study medication</term><term>Surrogate</term><term>Time points</term><term>Tolerability</term><term>Treatment difference</term><term>Treatment differences</term><term>Treatment groups</term><term>Trochanter</term><term>Turnover</term><term>Vertebral</term><term>Vertebral fracture</term><term>Vertebral fractures</term><term>Whitehouse</term><term>Whitehouse station</term><term>Woman</term><term>World</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Acide alendronique</term><term>Acide risédronique</term><term>Adulte</term><term>Antiostéoclastique</term><term>Antiostéoporotique</term><term>Antirésorptif</term><term>Densité minérale osseuse</term><term>Etude comparative</term><term>Femelle</term><term>Femme</term><term>International</term><term>Monde</term><term>Médecine</term><term>Ostéoporose</term><term>Postménopause</term><term>Résultat</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Alendronate</term><term>Alendronate risedronate</term><term>Antiresorptive</term><term>Antiresorptive agents</term><term>April</term><term>Base study</term><term>Baseline</term><term>Baseline month</term><term>Biochemical markers</term><term>Blackwell publishing</term><term>Bone density</term><term>Bone miner</term><term>Bone mineral density</term><term>Bone resorption</term><term>Bone strength</term><term>Bone turnover</term><term>Bone turnover markers</term><term>Clin</term><term>Clin endocrinol metab</term><term>Clin pract</term><term>Cohort</term><term>Critical revision</term><term>Data collection</term><term>Data interpretation</term><term>Extension study</term><term>Femoral</term><term>Femoral neck</term><term>Fracture</term><term>Fracture intervention trial</term><term>Fracture rates</term><term>Fracture risk</term><term>Fracture risk reductions</term><term>Greater increases</term><term>Journal compilation</term><term>Lumbar</term><term>Lumbar spine</term><term>Marker</term><term>Merck</term><term>Nonvertebral fractures</term><term>Osteoporosis</term><term>Percent change</term><term>Percentage change</term><term>Postmenopausal</term><term>Postmenopausal osteoporosis</term><term>Postmenopausal women</term><term>Pract</term><term>Resorption</term><term>Risedronate</term><term>Risedronate treatment</term><term>Study medication</term><term>Surrogate</term><term>Time points</term><term>Tolerability</term><term>Treatment difference</term><term>Treatment differences</term><term>Treatment groups</term><term>Trochanter</term><term>Turnover</term><term>Vertebral</term><term>Vertebral fracture</term><term>Vertebral fractures</term><term>Whitehouse</term><term>Whitehouse station</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adulte</term><term>Collecte de données</term><term>Chiffre d'affaires</term><term>Femme</term><term>Médecine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Objectives: To compare alendronate 70 mg once weekly (OW) with risedronate 35 mg OW with respect to change in bone mineral density (BMD), biochemical markers and upper gastrointestinal (UGI) tolerability over 24 months.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Brésil</li><li>Canada</li><li>France</li><li>Italie</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Grand Est</li><li>Lorraine (région)</li><li>New Jersey</li><li>Victoria (État)</li><li>État de São Paulo</li></region><settlement><li>Melbourne</li><li>Nancy</li><li>São Paulo</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Reid, D M" sort="Reid, D M" uniqKey="Reid D" first="D. M." last="Reid">D. M. Reid</name></noRegion><name sortKey="Hosking, D" sort="Hosking, D" uniqKey="Hosking D" first="D." last="Hosking">D. Hosking</name></country><country name="Canada"><noRegion><name sortKey="Kendler, D" sort="Kendler, D" uniqKey="Kendler D" first="D." last="Kendler">D. Kendler</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Brandi, M L" sort="Brandi, M L" uniqKey="Brandi M" first="M. L." last="Brandi">M. L. Brandi</name></noRegion></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Wark, J D" sort="Wark, J D" uniqKey="Wark J" first="J. D." last="Wark">J. D. Wark</name></region></country><country name="Brésil"><region name="État de São Paulo"><name sortKey="Marques Eto, J F" sort="Marques Eto, J F" uniqKey="Marques Eto J" first="J. F." last="Marques-Neto">J. F. Marques-Neto</name></region></country><country name="France"><region name="Grand Est"><name sortKey="Weryha, G" sort="Weryha, G" uniqKey="Weryha G" first="G." last="Weryha">G. Weryha</name></region></country><country name="États-Unis"><region name="New Jersey"><name sortKey="Verbruggen, N" sort="Verbruggen, N" uniqKey="Verbruggen N" first="N." last="Verbruggen">N. Verbruggen</name></region><name sortKey="Hustad, C M" sort="Hustad, C M" uniqKey="Hustad C" first="C. M." last="Hustad">C. M. Hustad</name><name sortKey="Mahlis, E M" sort="Mahlis, E M" uniqKey="Mahlis E" first="E. M." last="Mahlis">E. M. Mahlis</name><name sortKey="Melton, M E" sort="Melton, M E" uniqKey="Melton M" first="M. E." last="Melton">M. E. Melton</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008900 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008900 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:207451C66668188CD2675BB430BD2EFDB6B6E70C
|texte= A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24‐month results from FACTS‐International
}}
| This area was generated with Dilib version V0.6.33. |  |